CN105658669A - 细胞因子拮抗剂的靶向 - Google Patents
细胞因子拮抗剂的靶向 Download PDFInfo
- Publication number
- CN105658669A CN105658669A CN201480040656.4A CN201480040656A CN105658669A CN 105658669 A CN105658669 A CN 105658669A CN 201480040656 A CN201480040656 A CN 201480040656A CN 105658669 A CN105658669 A CN 105658669A
- Authority
- CN
- China
- Prior art keywords
- cells
- fusion protein
- cytokine
- antibody
- antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13306045.9 | 2013-07-19 | ||
| EP13306045 | 2013-07-19 | ||
| PCT/EP2014/063976 WO2015007520A1 (en) | 2013-07-19 | 2014-07-01 | Targeting of cytokine antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105658669A true CN105658669A (zh) | 2016-06-08 |
Family
ID=48874233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480040656.4A Pending CN105658669A (zh) | 2013-07-19 | 2014-07-01 | 细胞因子拮抗剂的靶向 |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US9732135B2 (https=) |
| EP (1) | EP3022230B1 (https=) |
| JP (1) | JP6475712B2 (https=) |
| KR (1) | KR102305608B1 (https=) |
| CN (1) | CN105658669A (https=) |
| AU (1) | AU2014292355B2 (https=) |
| CA (1) | CA2918119C (https=) |
| IL (1) | IL243459B (https=) |
| MX (1) | MX375426B (https=) |
| SG (2) | SG10202010429YA (https=) |
| WO (1) | WO2015007520A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020156467A1 (zh) * | 2019-01-30 | 2020-08-06 | 复旦大学 | 人α干扰素受体结合相关位点突变体及其用途 |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104245734B (zh) * | 2012-01-20 | 2017-09-05 | 非营利性组织佛兰芒综合大学生物技术研究所 | 靶向突变体α‑螺旋束细胞因子 |
| CA2918119C (en) * | 2013-07-19 | 2022-11-29 | Centre Hospitalier Regional Universitaire De Montpellier | Targeting of ifn.alpha.2 antagonists to treat autoimmune diseases |
| US11702477B2 (en) | 2015-11-06 | 2023-07-18 | Orionis Biosciences BV | Bi-functional chimeric proteins and uses thereof |
| US11661455B2 (en) | 2016-02-05 | 2023-05-30 | Orionis Biosciences BV | Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety |
| US11001631B2 (en) | 2016-02-05 | 2021-05-11 | Orionis Biosciences BV | Clec9A binding agents |
| US11248057B2 (en) | 2016-03-07 | 2022-02-15 | Vib Vzw | CD20 binding single domain antibodies |
| WO2017153345A1 (en) * | 2016-03-07 | 2017-09-14 | Vib Vzw | Cd20 binding agents and uses thereof |
| WO2017194783A1 (en) | 2016-05-13 | 2017-11-16 | Orionis Biosciences Nv | Targeted mutant interferon-beta and uses thereof |
| CN109563141A (zh) * | 2016-05-13 | 2019-04-02 | 奥里尼斯生物科学公司 | 对非细胞结构的治疗性靶向 |
| CA3040802A1 (en) | 2016-10-24 | 2018-05-03 | Orionis Biosciences Nv | Targeted mutant interferon-gamma and uses thereof |
| CN110573172A (zh) | 2017-02-06 | 2019-12-13 | 奥里尼斯生物科学有限公司 | 靶向的工程化干扰素及其用途 |
| EP3577133A1 (en) | 2017-02-06 | 2019-12-11 | Orionis Biosciences NV | Targeted chimeric proteins and uses thereof |
| EP3580230B1 (en) | 2017-02-07 | 2026-04-22 | Vib Vzw | Immune-cell targeted bispecific chimeric proteins and uses thereof |
| JP7423511B2 (ja) | 2017-08-09 | 2024-01-29 | オリオンズ バイオサイエンス インコーポレイテッド | Ｐｄ－１およびｐｄ－ｌ１結合物質 |
| EP3665201A4 (en) * | 2017-08-09 | 2021-06-02 | Orionis Biosciences, Inc. | CD8 BINDERS |
| US12091463B2 (en) | 2017-08-09 | 2024-09-17 | Orionis Biosciences, Inc. | Clec9A binding agents comprising a recombinant heavy-chain only antibody (VHH) |
| US20200354424A1 (en) | 2018-01-26 | 2020-11-12 | Orionis Biosciences, Inc. | Xcr1 binding agents and uses thereof |
| JP2021513361A (ja) | 2018-02-05 | 2021-05-27 | オリオニス バイオサイエンシーズ，インコーポレイテッド | 線維芽細胞結合物質およびその使用 |
| WO2020033646A1 (en) | 2018-08-08 | 2020-02-13 | Orionis Biosciences, Inc. | SIRP1α TARGETED CHIMERIC PROTEINS AND USES THEREOF |
| US12410225B2 (en) | 2018-11-08 | 2025-09-09 | Orionis Biosciences, Inc | Modulation of dendritic cell lineages |
| CA3133648A1 (en) | 2019-03-28 | 2020-10-01 | Orionis Biosciences, Inc. | Fibroblast activation protein binding agents and use thereof |
| CN120590542A (zh) | 2019-03-28 | 2025-09-05 | 奥里尼斯生物科学股份有限公司 | 基于clec9a的嵌合蛋白复合物 |
| JP7689079B2 (ja) | 2019-03-28 | 2025-06-05 | オリオニス バイオサイエンシズ，インコーポレイテッド | 治療用インターフェロンアルファ１タンパク質 |
| WO2020257412A1 (en) | 2019-06-19 | 2020-12-24 | Orionis Biosciences, Inc. | Combination therapy with cd13-targeted chimeric proteins or chimeric protein complexes |
| KR20220035365A (ko) | 2019-07-18 | 2022-03-22 | 엔요 파마 | 인터페론의 부작용을 감소시키는 방법 |
| MX2023011310A (es) | 2021-03-26 | 2023-10-05 | Innate Pharma | Anclajes de citocina para proteinas de celulas nk de union a nkp46. |
| BR112023025331A2 (pt) | 2021-06-09 | 2024-02-27 | Innate Pharma | Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso |
| WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
| WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
| WO2024040247A1 (en) | 2022-08-18 | 2024-02-22 | Regeneron Pharmaceuticals, Inc. | Interferon proproteins and uses thereof |
| US20240067691A1 (en) | 2022-08-18 | 2024-02-29 | Regeneron Pharmaceuticals, Inc. | Interferon receptor agonists and uses thereof |
| AU2024274130A1 (en) | 2023-05-12 | 2026-01-08 | Regeneron Pharmaceuticals, Inc. | Interferon receptor antagonists and uses thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1382158A (zh) * | 1999-08-09 | 2002-11-27 | 利思进药品公司 | 多细胞因子－抗体复合物 |
| CN101868246A (zh) * | 2007-09-21 | 2010-10-20 | 加利福尼亚大学董事会 | 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性 |
| US20130183298A1 (en) * | 1991-03-18 | 2013-07-18 | New York University | Methods of Treating Hepatitis With Anti-TNF alpha Antibodies |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2055445T3 (es) | 1989-08-22 | 1994-08-16 | Immunex Corp | Proteinas de fusion que comprenden gm-csf e il-3. |
| US5914254A (en) | 1993-08-02 | 1999-06-22 | Celtrix Pharmaceuticals, Inc. | Expression of fusion polypeptides transported out of the cytoplasm without leader sequences |
| DE69733610T2 (de) * | 1996-04-26 | 2006-05-11 | Beth Israel Deaconess Medical Center, Inc., Boston | Interleukin-15 antagonisten |
| US20020193569A1 (en) * | 2001-06-04 | 2002-12-19 | Idec Pharmaceuticals Corporation | Bispecific fusion protein and method of use for enhancing effector cell killing of target cells |
| CA2585549A1 (en) | 2004-11-18 | 2006-05-26 | Vib Vzw | Novel type leptin receptor antagonist |
| WO2006115800A2 (en) | 2005-04-15 | 2006-11-02 | The Regents Of The University Of California | Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha |
| EP1909822B1 (en) * | 2005-06-29 | 2013-09-25 | Yeda Research And Development Co., Ltd. | Recombinant interferon alpha 2 (ifn alpha 2) mutants |
| WO2008014612A1 (en) | 2006-08-02 | 2008-02-07 | Mcgill University | Fusion proteins and methods for modulation of immune response |
| US11535673B2 (en) | 2007-04-05 | 2022-12-27 | President and Fellows of Harvard CoHege | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
| DK2160401T3 (da) * | 2007-05-11 | 2014-10-20 | Altor Bioscience Corp | Fusionsmolekyler og il-15-varianter |
| US20110038865A1 (en) | 2007-06-26 | 2011-02-17 | University Of Miami | Antibody- endostatin fusion protein and its variants |
| WO2010030671A1 (en) * | 2008-09-09 | 2010-03-18 | University Of Medicine And Dentistry Of New Jersey | Type i interferon antagonists |
| US8334101B2 (en) | 2008-09-26 | 2012-12-18 | University Of Massachusetts | Intracellular DNA receptor |
| JP2012510806A (ja) | 2008-12-08 | 2012-05-17 | コンプリクス エン ヴェー | 単鎖逆平行コイルドコイルタンパク質 |
| ES2534085T3 (es) | 2009-08-17 | 2015-04-17 | Roche Glycart Ag | Inmunoconjugados dirigidos |
| US20130115189A1 (en) | 2009-09-10 | 2013-05-09 | Cytos Biotechnology Ag | Use of Interleukin-1 Beta Mutein Conjugates in the Treatment of Diabetes |
| EP2718457A4 (en) | 2011-06-06 | 2014-12-24 | Immungene Inc | GENETICALLY MODIFIED FUSION MOLECULES LIGAND TNFSF-ANTIBODY ELEMENT |
| SG10201603411WA (en) * | 2011-10-28 | 2016-07-28 | Teva Pharmaceuticals Australia Pty Ltd | Polypeptide constructs and uses thereof |
| CN104245734B (zh) * | 2012-01-20 | 2017-09-05 | 非营利性组织佛兰芒综合大学生物技术研究所 | 靶向突变体α‑螺旋束细胞因子 |
| ES2800426T3 (es) | 2012-03-03 | 2020-12-30 | Immungene Inc | Moléculas de fusión anticuerpos-mutante de interferón modificadas |
| CA2918119C (en) * | 2013-07-19 | 2022-11-29 | Centre Hospitalier Regional Universitaire De Montpellier | Targeting of ifn.alpha.2 antagonists to treat autoimmune diseases |
-
2014
- 2014-07-01 CA CA2918119A patent/CA2918119C/en active Active
- 2014-07-01 SG SG10202010429YA patent/SG10202010429YA/en unknown
- 2014-07-01 JP JP2016526507A patent/JP6475712B2/ja active Active
- 2014-07-01 CN CN201480040656.4A patent/CN105658669A/zh active Pending
- 2014-07-01 KR KR1020167002677A patent/KR102305608B1/ko active Active
- 2014-07-01 EP EP14734166.3A patent/EP3022230B1/en active Active
- 2014-07-01 US US14/905,348 patent/US9732135B2/en active Active
- 2014-07-01 MX MX2016000721A patent/MX375426B/es active IP Right Grant
- 2014-07-01 AU AU2014292355A patent/AU2014292355B2/en active Active
- 2014-07-01 SG SG11201600165WA patent/SG11201600165WA/en unknown
- 2014-07-01 WO PCT/EP2014/063976 patent/WO2015007520A1/en not_active Ceased
-
2016
- 2016-01-04 IL IL24345916A patent/IL243459B/en active IP Right Grant
-
2017
- 2017-07-06 US US15/642,989 patent/US10072059B2/en active Active
-
2018
- 2018-06-14 US US16/008,695 patent/US20180334489A1/en not_active Abandoned
- 2018-06-14 US US16/008,686 patent/US10947288B2/en active Active
-
2021
- 2021-02-09 US US17/171,433 patent/US20210238247A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130183298A1 (en) * | 1991-03-18 | 2013-07-18 | New York University | Methods of Treating Hepatitis With Anti-TNF alpha Antibodies |
| CN1382158A (zh) * | 1999-08-09 | 2002-11-27 | 利思进药品公司 | 多细胞因子－抗体复合物 |
| CN101868246A (zh) * | 2007-09-21 | 2010-10-20 | 加利福尼亚大学董事会 | 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性 |
Non-Patent Citations (1)
| Title |
|---|
| MANJING PAN等: "Mutation of the IFNAR-1 Receptor Binding Site of Human IFN-R2 Generates Type I IFN Competitive Antagonists", 《BIOCHEMISTRY》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020156467A1 (zh) * | 2019-01-30 | 2020-08-06 | 复旦大学 | 人α干扰素受体结合相关位点突变体及其用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20160108292A (ko) | 2016-09-19 |
| MX2016000721A (es) | 2016-09-07 |
| AU2014292355B2 (en) | 2019-08-01 |
| IL243459A0 (en) | 2016-03-31 |
| US20210238247A1 (en) | 2021-08-05 |
| SG11201600165WA (en) | 2016-02-26 |
| MX375426B (es) | 2025-03-06 |
| JP2016529232A (ja) | 2016-09-23 |
| EP3022230B1 (en) | 2019-11-06 |
| US20160159875A1 (en) | 2016-06-09 |
| US20180334488A1 (en) | 2018-11-22 |
| EP3022230A1 (en) | 2016-05-25 |
| AU2014292355A1 (en) | 2016-02-04 |
| CA2918119A1 (en) | 2015-01-22 |
| CA2918119C (en) | 2022-11-29 |
| US9732135B2 (en) | 2017-08-15 |
| KR102305608B1 (ko) | 2021-09-28 |
| US20180334489A1 (en) | 2018-11-22 |
| SG10202010429YA (en) | 2020-11-27 |
| US10072059B2 (en) | 2018-09-11 |
| US10947288B2 (en) | 2021-03-16 |
| JP6475712B2 (ja) | 2019-02-27 |
| US20180057555A1 (en) | 2018-03-01 |
| WO2015007520A1 (en) | 2015-01-22 |
| IL243459B (en) | 2019-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10947288B2 (en) | Targeting of human interferon antagonists | |
| Duchesne et al. | Epithelial cell alarmin cytokines: Frontline mediators of the asthma inflammatory response | |
| Larochette et al. | IL-26, a cytokine with roles in extracellular DNA-induced inflammation and microbial defense | |
| Adams et al. | Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F | |
| Wolk et al. | Biology of interleukin-22 | |
| Bitton et al. | A key role for IL-13 signaling via the type 2 IL-4 receptor in experimental atopic dermatitis | |
| Conti et al. | IL-17 receptor signaling in oral epithelial cells is critical for protection against oropharyngeal candidiasis | |
| Whibley et al. | Antibody blockade of IL-17 family cytokines in immunity to acute murine oral mucosal candidiasis | |
| AU2019201007B2 (en) | Novel specific-binding polypeptides and uses thereof | |
| Hernandez‐Santana et al. | Current perspectives on the interleukin‐1 family as targets for inflammatory disease | |
| JP2009543579A (ja) | 抗炎症反応のための標的としてのＷＳＸ−１／ｐ２８ | |
| Morandi et al. | A novel mechanism of soluble HLA-G mediated immune modulation: downregulation of T cell chemokine receptor expression and impairment of chemotaxis | |
| US20050214296A1 (en) | Methods of modulating cytokine activity; related reagents | |
| Martinez-Martinez et al. | A novel gain-of-function STAT1 mutation resulting in basal phosphorylation of STAT1 and increased distal IFN-γ-mediated responses in chronic mucocutaneous candidiasis | |
| Sabat et al. | IL-22 and IL-17: an overview | |
| Hammitzsch et al. | Increased interleukin-26 in the peripheral joints of patients with axial spondyloarthritis and psoriatic arthritis, co-localizing with CD68-positive synoviocytes | |
| Class et al. | Patent application title: TARGETING OF CYTOKINE ANTAGONISTS | |
| HK1225047A1 (en) | Targeting of cytokine antagonists | |
| HK1225047B (en) | Targeting of Cytokine Antagonists | |
| BR112016001122B1 (pt) | Proteína de fusão compreendendo um antagonista de interferon e uma fração de direcionamento | |
| Hou et al. | IL‑22 expression is increased variedly in the initial phase, onset and chronic phase of a pristane‑induced arthritis rat model | |
| Skouris | Investigating the action mechanisms of IL-12 and IL-23 in an experimental model of Crohn’s disease | |
| Tomankova et al. | Articles in PresS. Am J Physiol Lung Cell Mol Physiol (January 30, 2015). doi: 10.1152/ajplung. 00203.2014 | |
| MXPA06009438A (en) | Agonists and antagonists of p28 ebi3 and wsx/tccr for treating immune disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: Ghent Applicant after: Univ Gent Applicant after: Universiteit Gent Applicant after: Centre National De La Recherche Scientifique Applicant after: Universite De Montpellier Applicant after: CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER Address before: Ghent Applicant before: Univ Gent Applicant before: Universiteit Gent Applicant before: Centre National De La Recherche Scientifique Applicant before: Univ. Montpellier II Applicant before: CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER |
|
| CB02 | Change of applicant information |